COVID-19 impacting Cell&Gene therapy manufacturing Webinar | molmed
MolMed, Fininvest aderisce all'OPA e cede quota 23,1%
Molmed, Opa dei giapponesi di Agc. Per Berlusconi 30 milioni di plusvalenza - Affaritaliani.it
Prezzi da saldo a Piazza Affari, rischio Opa straniere. Giapponesi su MolMed
MolMed - YouTube
1 - [Note: this notice is the English translation of the official version of the 102 notice which will be in Italian language]
Small Cap Conference 2013: listed SMEs meet investors at Borsa Italiana
MolMed - Wikipedia
Meeting agenda | molmed
MolMed now part of AGC Biologics | LinkedIn
European Population Genetic Substructure: Further Definition of Ancestry Informative Markers for Distinguishing among Diverse European Ethnic Groups | Molecular Medicine | Full Text
Voluntary Tender Offer launched by AGC Inc. on all ordinary shares of MolMed: the Board of Directors approves the Issuer's not
home | molmed
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHER
MOLMED S.P.A.: MLM Azione Prezzo| IT0001080248 | MarketScreener
MolMed to test the health of the European sector | Evaluate
MolMed now part of AGC Biologics | LinkedIn
Molmed, la giapponese Agc supera il 50% in Opa - Il Sole 24 ORE
MolMed lascia Piazza Affari dopo Opa di Agc - Borse.it
MolMed non vuole il golden power: «Offerta Agc conveniente per tutti» - Il Sole 24 ORE
Will MolMed soon have its first Cell therapy on the Market?
European Population Genetic Substructure: Further Definition of Ancestry Informative Markers for Distinguishing among Diverse European Ethnic Groups | Molecular Medicine | Full Text
